Skip to main content
梓橦宫 logo

梓橦宫 — Investor Relations & Filings

Ticker · 920566 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 625 across all filing types
Latest filing 2024-07-22 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920566

About 梓橦宫

http://www.zitonggong.com/

Zitonggong specializes in the research, development, and production of specialized therapeutic agents. Established with a heritage dating back to 1780, the company holds a recognized heritage brand designation. Its primary product portfolio centers on neurological and cerebrovascular health, featuring Oxiracetam in various dosage forms for treating cognitive dysfunction and brain injuries. The company also develops treatments for digestive health, including Compound Aloe Capsules, and produces artificial Oriental Bezoar. Operations are centered on integrating traditional medicinal knowledge with modern chemical synthesis and manufacturing standards. The company maintains a focus on clinical efficacy and technological advancement in the fields of neurology and gastroenterology.

Recent filings

Filing Released Lang Actions
上海天璇律师事务所关于四川梓橦宫药业股份有限公司2023年股权激励计划预留授予事项之法律意见书
Regulatory Filings
2024-07-22 Chinese
第四届董事会第六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the sixth meeting of the fourth board of directors of Sichuan Zitonggong Pharmaceutical Co., Ltd. It details the meeting's attendance, the agenda items discussed, voting results, and references to related announcements on the Beijing Stock Exchange information disclosure platform. The content focuses on board decisions such as granting restricted stock, changes to fundraising project implementation, and scheduling a shareholders' meeting. There are no financial statements or detailed financial data presented, nor is this a transcript or presentation. The document is clearly a board meeting resolution announcement, which fits the category of Board/Management Information (MANG). The document length is short (1808 characters), and it is not merely announcing the publication of a report but is itself the meeting resolution announcement. Therefore, the correct classification is MANG with high confidence.
2024-07-22 Chinese
关于拟减少注册资本通知债权人的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Sichuan Zitonggong Pharmaceutical Co., Ltd. regarding a proposed reduction in registered capital due to the repurchase and cancellation of restricted shares related to an equity incentive plan. It includes details about the board and shareholder meetings approving the reduction, the change in share capital, and a notification to creditors to declare their claims within 45 days. The document is a formal notice to creditors and shareholders about the capital reduction and related procedures, not a financial report, earnings release, or management discussion. It is a regulatory announcement informing stakeholders of corporate actions and legal compliance requirements. Therefore, it fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2024-07-22 Chinese
关于向激励对象授予预留限制性股票的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the granting of reserved restricted shares under a 2023 equity incentive plan by Sichuan Zitonggong Pharmaceutical Co., Ltd. It includes information about board and shareholder meetings approving the plan, conditions for granting, number of shares, pricing, performance targets, and legal and financial advisor opinions. The content focuses on the equity incentive plan implementation and related approvals rather than a full financial report or earnings release. It is not a full annual or interim report, nor a call transcript or audit report. It is a formal announcement about a capital/financing activity related to share-based compensation and equity incentives. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (8238 characters) and detailed content support this classification with high confidence.
2024-07-22 Chinese
上海荣正企业咨询服务（集团）股份有限公司关于四川梓橦宫药业股份有限公司2023年股权激励计划预留授予相关事项之独立财务顾问报告
Regulatory Filings
2024-07-22 Chinese
关于变更部分募投项目的实施方式及延期的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Sichuan Zitonggong Pharmaceutical Co., Ltd. regarding changes in the implementation method and extension of certain projects funded by raised capital. It details the use and storage of raised funds, changes in project investment plans, reasons for changes, and the impact on the company. It includes meeting resolutions and opinions from the sponsor institution. The content focuses on updates related to capital raised through share issuance and its usage, rather than a full financial report or earnings release. This fits the definition of a Capital/Financing Update (CAP) as it provides updates on fundraising and capital usage.
2024-07-22 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.